Table of Contents
Artios:
| Type | Private | |
| Founded | 2016 | |
| HQ | Cambridgeshire, GB | |
| Website | artiospharma.com |
Novartis to use Artios’ revelation stage to distinguish DDR focuses for use with Novartis’ exclusive radioligand treatments. Artios to get US$20 million front and center installment notwithstanding close to term research financing to help the cooperation.
Artios qualified to get up to $1.3 billion in revelation, improvement, administrative and deals based achievements notwithstanding eminence installments.
Artios Pharma Limited (Artios), a main DNA Damage Response (DDR) organization taking advantage of engineered lethality to foster an expansive pipeline of accuracy meds for the therapy of disease, today declared a worldwide exploration joint effort with Novartis to find and approve cutting edge DDR focuses to upgrade Novartis’ Radioligand Therapies (RLT).
Under the three-year cooperation, Artios and Novartis will perform target disclosure and approval, and Novartis will choose up to three selective DDR targets, and get overall privileges on these objectives to be used with its Rlt’s.
Artios is a main free DNA Damage Response (DDR) organization focussed on growing first-in-class therapies for malignant growth. Laid out in May 2016, the Company is driven by an accomplished logical and initiative group with demonstrated mastery in DDR drug disclosure.
Artios is building a pipeline of cutting edge DDR programs, including through a remarkable organization with Cancer Research Technology (CRT), the turn of events and commercialisation arm of Cancer Research UK (CRUK), and with driving DNA fix analysts around the world.
The Company’s financial backers incorporate SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (oversaw by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Latest News
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications
CAMBRIDGE, United Kingdom and NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) – – Artios Pharma Limited (Artios), a main DNA Damage Response (DDR) organization taking advantage of a wide DDR-based stage and little particle drug plan capacities to foster an assorted pipeline of item contender for the treatment
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
CAMBRIDGE, England and NEW YORK, Feb. 11, 2021/PRNewswire/ – – Artios Pharma Limited (“Artios”), a main DNA Damage Response (DDR) organization fostering an expansive pipeline of accuracy prescriptions for the therapy of malignant growth, today declared the beginning of a clinical preliminary of its little particle
Artios Pharma Funding
| Founding Date | 2016 |
| Artios Pharma total Funding | $116.1 m |
| Artios Pharma latest funding size | $83.61 m |
| Time since last funding | 4 years ago |
| Artios Pharma investors | SV Life Sciences, Novartis Venture Fund, Imperial Innovations, AbbVie Biotech Ventures, LSP, Merck Ventures, Arix Bioscience, SV Health Investors, M Ventures, Andera Partners, Pfizer Ventures, AbbVie Ventures, IP Group |
Artios Pharma’s latest funding round in August 2018 was reported to be $83.6 m. In total, Artios Pharma has raised $116.1 m
Artios Pharma Income Statement
Annual
| GBP | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
| EBITDA | (2.9m) | (5.7m) | (9.6m) |
| EBIT | (2.9m) | (5.7m) | (9.8m) |
| Pre tax profit | (2.9m) | (6.0m) | (10.9m) |
| Income tax expense | 490.0k | 1.1m | 1.9m |
| Net Income | (2.4m) | (4.9m) | (9.0m) |
Competitors
E&O LABORATORIES
E and O Laboratories is a supplier of biotechnology administrations.
NOVELLUSDX
NovellusDx is committed to conveying the significant knowledge that oncologists expect to pick the right treatment for every persistent. NovellusDx gives exhaustive, completely robotized, utilitarian quality profiling of individual patient growths including graphing the full scene of known and obscure transformations that drive the disease’s movement.
UNUM THERAPEUTICS
Malignant growth cell treatment organization fostering a stage to couple cancer explicit antibodies to the body’s own safe framework.
BIENA
Biena is an organization that produces bacterial societies.
ITS PEOPLE
Chief Executive Officer
Niall has extensive experience in the DDR field and in cancer therapeutics in general, both in small companies and pharma.
Prior to joining Artios, Niall was a co-founder and Chief Operating Officer at MISSION Therapeutics, a company focused on the commercialisation of expert research into ubiquitin pathways for the treatment of cancers and other diseases. During his time at MISSION, Niall helped establish the deubiquitylating enzyme (DUB) inhibitor platform, and raise more than £80 million in Series A and B financing.
CONCLUSION
DDR field has been clinically validated by the success of PARP inhibitors, currently becoming a multi-billion-dollar drug class in a range of cancers. Key Artios executives played an integral role in the discovery and development of LynparzaÒ (olaparib), the first PARP inhibitor to market, when at Kudos Pharmaceuticals and later AstraZeneca.
Artios is now a leader in next generation DDR, developing a pipeline of three highly promising new DDR therapies, led by PolƟ which is attracting industry attention.
